

## OSENI - (12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet)

|                              |                                                                                                                                                                                      |                             |                     |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE                                                                                                                                      | <b>Innovator</b>            | Takeda              |
| <b>Dosage</b>                | 12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet                                                                                                                                            | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                          | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                          | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None                                                                                                                                                                                 | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.